Q
Qingjie Ding
Researcher at Hoffmann-La Roche
Publications - 26
Citations - 1285
Qingjie Ding is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Cyclin-dependent kinase & Cancer. The author has an hindex of 12, co-authored 26 publications receiving 1108 citations.
Papers
More filters
Journal ArticleDOI
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development.
Qingjie Ding,Zhuming Zhang,Jin-Jun Liu,Nan Jiang,Jing Zhang,Tina Morgan Ross,Xin-Jie Chu,David Joseph Bartkovitz,Frank John Podlaski,Cheryl Janson,Christian Tovar,Zoran Filipovic,Brian Higgins,Kelli Glenn,Packman Kathryn E,Lyubomir T. Vassilev,Bradford Graves +16 more
TL;DR: The discovery and characterization of a second generation clinical MDM2 inhibitor, RG7388, with superior potency and selectivity is reported, with a significant challenge for the development of small-molecule inhibitors with desirable pharmacological profiles.
Journal ArticleDOI
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
Binh Thanh Vu,Peter Michael Wovkulich,Giacomo Pizzolato,Allen John Lovey,Qingjie Ding,Nan Jiang,Jin-Jun Liu,Chunlin Zhao,Kelli Glenn,Yang Wen,Christian Tovar,Packman Kathryn E,Lyubomir T. Vassilev,Bradford Graves +13 more
TL;DR: RG7112 is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket ofMDM2, which stabilizes p53 and activates the p 53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Journal ArticleDOI
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Xin-Jie Chu,Wanda DePinto,David Joseph Bartkovitz,Sung-Sau So,Binh Thanh Vu,Packman Kathryn E,Christine Lukacs,Qingjie Ding,Nan Jiang,Ka Wang,Petra Goelzer,Xuefeng Yin,Melissa Smith,Brian Higgins,Yingsi Chen,Qing Xiang,John Anthony Moliterni,Kaplan Gerald Lewis,Bradford Graves,Allen John Lovey,Nader Fotouhi +20 more
TL;DR: The 2,4-diamino-5-ketopyrimidines 6 reported here represent a novel class of potent and ATP-competitive inhibitors that selectively target the cyclin-dependent kinase family, and compound 39 demonstrates significant in vivo efficacy in the HCT116 human colorectal tumor xenograft model in nude mice with up to 95% tumor growth inhibition.
Patent
Substituted pyrrolidine-2-carboxamides
David Joseph Bartkovitz,Xin-Jie Chu,Qingjie Ding,Nan Jiang,Jin-Jun Liu,Tina Morgan Ross,Jing Zhang,Zhuming Zhang +7 more
TL;DR: In this article, the authors provided compounds of the formula (I) wherein X, Y, R1, R2, R3, R4, R5, R6 and R7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof.
Journal ArticleDOI
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.
Zhuming Zhang,Xin-Jie Chu,Jin-Jun Liu,Qingjie Ding,Jing Zhang,David Joseph Bartkovitz,Nan Jiang,Prabha Karnachi,Sung-Sau So,Christian Tovar,Zoran Filipovic,Brian Higgins,Kelli Glenn,Packman Kathryn E,Lyubomir T. Vassilev,Bradford Graves +15 more
TL;DR: Two new potent, selective, and orally active p53-MDM2 antagonists are reported, RO5353 and RO2468, as follow-ups with promising potential for clinical development.